ИСТИНА

Aim of study was to examine effect of treatment β-blocker bisoprolol on the quality of life in patients with arterial hypertension (AH), peripheral and central pressure, diastolic function of left ventricular (DFLV), and arterial stiffness. Materials and methods. 30 patients (aged 54,5±10,5), 10 men, 20 women and HR≥75. All patients were evaluated blood pressure, resting heart rate, augmentation index (AI%), systolic (SPAo) and pulse pressure (PPAo) in the aorta (SphygmoCor, Atcor), pulse wave velocity in the carotid-femoral (PWVkf) and ankle- brachial (PWVab) segments. The levels of total cholesterol, triglycerides, creatinine, fasting blood glucose. Quality of life (QL) was assessed using a questionnaire MOS SF 36. All examinations were conducted at baseline and after 3 months of treatment with bisoprolol (in the average daily dose of 3,6 ± 1,5 mg). Results. On therapy SBP significantly decreased by 10.5%, DBP on 11.8%. When SPAo significant decrease (from 142.7 to 136.6 mm Hg) and PPAo (from 49.7 to 43.3 mm Hg), AI% increase (from 31.5 to 35.2 ). Bisoprolol reduced heart rate from 81.1 to 68.7 beats / min (p <0.001), improved mental and physical components of health, and also showed good tolerability and metabolic neutrality. PVWkf (-11.5%) and PVWab (-7.5%) was significantly decreased. Thus, in addition to improving quality of life in patients with hypertension, bisoprolol demonstrated a positive impact on the "surrogate" markers of prognosis - PWV, pulse and systolic pressure in the aorta.